Latest News

Kalbe To Distibute Dividend Of Rp 891 Billion

Kalbe To Distibute Dividend Of Rp 891 Billion

Press Release No. 008/KFCP-DIR/PR/V/15


Jakarta, May 18, 2015 – PT Kalbe Farma Tbk (“Kalbe” or “the Company”) will distribute cash dividend of Rp 891 billion. The dividend distribution of Rp 19 per share or equivalent to a dividend payout ratio of around 43% of fiscal year 2014 net income, has been approved by the shareholders of the Company in the Annual General Meeting of Shareholders (“AGMS”) held on May 18, 2015 in Gedung Bintang Toedjoe, Pulomas, Jakarta. In compliance with the prevailing regulations, dividend payment will be made at the latest within 30 days after the announcement of AGMS where the Company will shortly announce the schedule and procedures.

“As part of our commitment to provide an optimal return to the shareholders, we will distribute cash dividend of Rp 891 billion,” stated Vidjongtius as the Company’s Director and Corporate Secretary. “Despite the challenging market situation this year, the Company remains optimistic of the future growth potentials, and has allocated fund for capital expenditure for capacity expansion. Taking into account the market condition, as well as cash requirement for operational and investment, we will distribute dividend of 43% of 2014 net income to the shareholders. Going forward, we maintain our policy to distribute around 40 – 50% payout ratio, after taking into consideration the expansion plan and cash requirement.”

In the AGMS, the Company has also obtained the approval of the shareholders on the following agenda:

 Approval of the Annual Report of the Company for the year ended December 31, 2014, including the Activity Report of the Company, the Report of the Supervisory Role of the  Board of Commissioners, approval and ratification of the Company’s Audited Financial Statements for the year ended December 31, 2014 and to grant a release and discharge from their responsibilities to all members of the Board of Commissioners and Board of Directors for their management and supervision actions during the financial year ended December 31, 2014 (acquit et decharge);


Approval on the appropriation of the Company’s Net Profits for the financial year ended December 31, 2014;
Changes in the composition of the Board of Commissioners and the Board of Directors of the Company;
Determination of salary and/or honorarium of the members of the Board of Commissioners and the Board of Directors and to authorize the Board of Commissioners to determine the salary and/or honorarium of the members of the Company’s Board of Commissioners and Board of Directors;
Appointment of Independent Public Accountant to audit the Company’s Financial Statements for the year ended December 31, 2015 and authorize the Board of Directors to determine the honorarium of the Independent Public Accountant and other appointment’s conditions.


The members of the Board of Commissioners and Board of Directors since the closing of this AGMS until 2017 are as follows:

Board of Commissioners
President Commissioner: JOHANNES SETIJONO;
Commissioner : SANTOSO OEN;
Commissioner: FERDINAND ARYANTO;
Independent Commissioner : FARID ANFASA MOELOEK;
Independent Commissioner : LUCKY SURJADI SLAMET;
Commissioner: RONNY HADIANA

Board of Directors
President Director: BERNADETTE RUTH IRAWATI SETIADY;
Independent Director: VIDJONGTIUS;
Director : ONGKIE TEDJASURJA;
Director: BUJUNG NUGROHO;
Director: DJONNY HARTONO TJAHYADI

On the same day, the Company also conducted Extraordinary General Meeting of Shareholders (EGMS) that have approved amendment of the Articles of Association of the Company to comply with the stipulation of the Financial Services Authority Regulations.

Kalbe at a Glance
PT Kalbe Farma Tbk. (“Kalbe”) was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions managing a broad and strong portfolio of brands; prescription pharmaceuticals division (Cefspan, Brainact, Broadced, etc), consumer health division comprising over-the-counter drugs (Promag, Mixagrip, Komix, Woods, Fatigon, etc) as well as ready-to-drink and energy drink products (Hydro Coco, Extra Joss, Nitros), nutritionals division (ChilKid, Prenagen, Diabetasol, etc), and distribution division. Kalbe currently has more than 20 subsidiaries and 9 production facilities with international standards, supported by around 17,000 employees and 6,000 sales and marketing personnel, spread in 70 branches across Indonesia.  Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).

Print
2282 Rate this article:
No rating

Please login or register to post comments.

Name:
Email:
Subject:
Message:
x